Recipient of Padma Bhushan in 2025, Shri Pankaj R Patel was the Chairman of which of the following pharmaceutical companies of India in April 2025?

Correct option is B

The correct answer is (b) Zydus Lifesciences Limited
Explanation:
· Shri Pankaj R Patel has been associated with Zydus Lifesciences as its long-standing Chairman.
· He played a central role in expanding the company's research, innovation, and global presence.
· In 2025, his leadership influence in the pharmaceutical sector was recognized with the Padma Bhushan award.
· Zydus is known for producing vaccines, biologics, and a wide range of medicines, making it a key contributor to India's healthcare industry.
· Patel’s contributions strengthened India’s pharmaceutical manufacturing and export capabilities.
· His efforts in improving drug accessibility and developing advanced therapeutic solutions were significant.
· The organization grew under his guidance through diversification of product lines and investment in innovation.
· His recognition highlights the contributions of private-sector leaders to national health development.
Information Booster:
· Zydus is among India's major drug research companies, producing vaccines, generics, and specialty formulations.
· The company expanded globally under his strategic leadership.
Additional Knowledge (Incorrect Options):
Sun Pharmaceutical Industries
· India’s largest pharma company by market capitalization, with a market value of around ₹4.3 lakh crore as of December 2025.
· Focuses on branded and generic formulations, specialty products (especially in dermatology and ophthalmology), and has a major presence in the US and global generic markets.
· The share price is around ₹1,790–1,800 per share on 11 December 2025, reflecting its leadership status and consistent profitability.
Zydus Lifesciences Limited
· A fully integrated healthcare group and one of India’s top pharma manufacturers, with more than 30 plants worldwide and operations in over 50 countries.
· Operates across the value chain: APIs, formulations, vaccines, biosimilars, complex products, animal health and wellness, with notable innovations like its NCE Lipaglyn for diabetic dyslipidemia.
· Recognized among the leading Indian pharma companies alongside Sun Pharma, Cipla, and Dr. Reddy’s.
Cipla Limited
· One of the top three pharma companies in India by market cap and a major global generics player, present in over 80 countries with more than 1,500 products across many therapies.
· Strong leadership in respiratory medicine in India, with significant shares in inhalation and nebulisation, and sizeable businesses in North America, Africa, and emerging markets.
· Market capitalization is in the ₹1.2–1.3 lakh crore range, placing it among India’s leading pharma majors.
Dr. Reddy’s Laboratories
· A multinational pharma company headquartered in Hyderabad, founded in 1984, with businesses in APIs, generics, branded generics, biosimilars, and OTC products.
· Operates in many countries worldwide, supplying a broad range of medications and APIs.
· Market cap is around ₹1.0 lakh crore, and the share trades near ₹1,250 per share as of 10 December 2025.